CYAD Profile
Celyad Oncology SA, a clinical-stage biopharmaceutical firm, specializes in pioneering the discovery and advancement of innovative chimeric antigen receptor T (CAR-T) cell therapies aimed at combating cancer. At the forefront of its portfolio are leading product candidates such as CYAD-101, an allogeneic CAR-T therapy currently undergoing Phase 1b clinical trials for the treatment of metastatic colorectal cancer. Additionally, CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, is in Phase 1 clinical trials targeting relapsed/refractory multiple myeloma. Further expanding its therapeutic reach, CYAD-02, an autologous CAR-T candidate, is under Phase 1 clinical investigation for treating relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
Complementing its clinical pipeline, Celyad Oncology SA is actively advancing preclinical candidate CYAD-203, a non-gene edited allogeneic CAR-T therapy engineered to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D), with a focus on addressing solid tumors. The company has strategically established partnerships to bolster its research and development initiatives, including a licensing agreement with Novartis International AG pertaining to United States patents related to allogeneic CAR-T cells. Additionally, collaboration and license agreements with Horizon Discovery Group plc facilitate the utilization of its shRNA technology, augmenting Celyad Oncology's capacity to generate a second non-gene-edited allogeneic platform.
Founded in 2004 and headquartered in Mont-Saint-Guibert, Belgium, Celyad Oncology SA, formerly known as Celyad SA, underwent a rebranding in June 2020 to reflect its sharpened focus on oncological innovations. Positioned at the forefront of CAR-T therapy development, Celyad Oncology SA is committed to revolutionizing cancer treatment paradigms and improving patient outcomes through its cutting-edge research and development endeavors.
|
